JCR Pharmaceuticals Co., Ltd. (4552.T)
JPY 610.0
(-0.81%)
JPY 610.0
(-0.81%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 45.74 Billion JPY | 7.58% |
| 2022 | 42.52 Billion JPY | -7.65% |
| 2021 | 46.04 Billion JPY | 30.7% |
| 2020 | 35.23 Billion JPY | 131.83% |
| 2019 | 15.19 Billion JPY | 30.5% |
| 2018 | 11.64 Billion JPY | 7.12% |
| 2017 | 10.87 Billion JPY | 23.55% |
| 2016 | 8.79 Billion JPY | 6.22% |
| 2015 | 8.28 Billion JPY | 5.92% |
| 2014 | 7.82 Billion JPY | -11.96% |
| 2013 | 8.88 Billion JPY | 14.03% |
| 2012 | 7.79 Billion JPY | 22.99% |
| 2011 | 6.33 Billion JPY | -9.32% |
| 2010 | 6.98 Billion JPY | -19.38% |
| 2009 | 8.66 Billion JPY | 11.33% |
| 2008 | 7.78 Billion JPY | 5.64% |
| 2007 | 7.36 Billion JPY | 3.0% |
| 2006 | 7.15 Billion JPY | 34.37% |
| 2005 | 5.32 Billion JPY | -29.66% |
| 2004 | 7.56 Billion JPY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 48.49 Billion JPY | 0.69% |
| 2024 Q2 | 47.57 Billion JPY | 9.45% |
| 2023 Q1 | 42.81 Billion JPY | 0.69% |
| 2023 Q3 | 46.82 Billion JPY | -0.09% |
| 2023 Q2 | 46.86 Billion JPY | 9.45% |
| 2023 Q4 | 45.74 Billion JPY | -2.29% |
| 2023 FY | 45.74 Billion JPY | 7.58% |
| 2022 Q2 | 38.51 Billion JPY | -7.25% |
| 2022 Q4 | 42.52 Billion JPY | 7.87% |
| 2022 FY | 42.52 Billion JPY | -7.65% |
| 2022 Q1 | 41.52 Billion JPY | -9.83% |
| 2022 Q3 | 39.42 Billion JPY | 2.36% |
| 2021 Q3 | 43.97 Billion JPY | 11.01% |
| 2021 Q4 | 46.04 Billion JPY | 4.71% |
| 2021 FY | 46.04 Billion JPY | 30.7% |
| 2021 Q1 | 37.15 Billion JPY | 5.45% |
| 2021 Q2 | 39.61 Billion JPY | 6.62% |
| 2020 Q1 | 23.53 Billion JPY | 54.89% |
| 2020 Q4 | 35.23 Billion JPY | 11.45% |
| 2020 FY | 35.23 Billion JPY | 131.83% |
| 2020 Q2 | 26.23 Billion JPY | 11.47% |
| 2020 Q3 | 31.61 Billion JPY | 20.48% |
| 2019 Q1 | 11.06 Billion JPY | -5.02% |
| 2019 FY | 15.19 Billion JPY | 30.5% |
| 2019 Q3 | 13.91 Billion JPY | -3.04% |
| 2019 Q4 | 15.19 Billion JPY | 9.21% |
| 2019 Q2 | 14.35 Billion JPY | 29.77% |
| 2018 Q1 | 10.36 Billion JPY | -4.67% |
| 2018 FY | 11.64 Billion JPY | 7.12% |
| 2018 Q4 | 11.64 Billion JPY | 9.21% |
| 2018 Q3 | 10.66 Billion JPY | 0.4% |
| 2018 Q2 | 10.62 Billion JPY | 2.48% |
| 2017 Q1 | 9.64 Billion JPY | 9.62% |
| 2017 FY | 10.87 Billion JPY | 23.55% |
| 2017 Q2 | 11.6 Billion JPY | 20.35% |
| 2017 Q4 | 10.87 Billion JPY | -13.95% |
| 2017 Q3 | 12.63 Billion JPY | 8.82% |
| 2016 Q4 | 8.79 Billion JPY | -3.82% |
| 2016 FY | 8.79 Billion JPY | 6.22% |
| 2016 Q3 | 9.14 Billion JPY | -7.0% |
| 2016 Q2 | 9.83 Billion JPY | -1.62% |
| 2016 Q1 | 9.99 Billion JPY | 20.71% |
| 2015 Q3 | 8.64 Billion JPY | 0.09% |
| 2015 Q2 | 8.63 Billion JPY | 4.63% |
| 2015 Q1 | 8.25 Billion JPY | 5.52% |
| 2015 Q4 | 8.28 Billion JPY | -4.15% |
| 2015 FY | 8.28 Billion JPY | 5.92% |
| 2014 FY | 7.82 Billion JPY | -11.96% |
| 2014 Q4 | 7.82 Billion JPY | -4.51% |
| 2014 Q3 | 8.19 Billion JPY | -14.4% |
| 2014 Q2 | 9.56 Billion JPY | 6.13% |
| 2014 Q1 | 9.01 Billion JPY | 1.5% |
| 2013 FY | 8.88 Billion JPY | 14.03% |
| 2013 Q1 | 8.31 Billion JPY | 6.68% |
| 2013 Q2 | 8.14 Billion JPY | -1.99% |
| 2013 Q3 | 7.39 Billion JPY | -9.19% |
| 2013 Q4 | 8.88 Billion JPY | 20.1% |
| 2012 Q2 | 7.9 Billion JPY | 21.21% |
| 2012 Q4 | 7.79 Billion JPY | 0.72% |
| 2012 FY | 7.79 Billion JPY | 22.99% |
| 2012 Q1 | 6.52 Billion JPY | 2.98% |
| 2012 Q3 | 7.73 Billion JPY | -2.18% |
| 2011 FY | 6.33 Billion JPY | -9.32% |
| 2011 Q4 | 6.33 Billion JPY | -5.9% |
| 2011 Q3 | 6.73 Billion JPY | -7.94% |
| 2011 Q2 | 7.31 Billion JPY | -8.36% |
| 2011 Q1 | 7.97 Billion JPY | 14.23% |
| 2010 Q3 | 7.35 Billion JPY | 0.97% |
| 2010 Q4 | 6.98 Billion JPY | -5.09% |
| 2010 FY | 6.98 Billion JPY | -19.38% |
| 2010 Q1 | 7.54 Billion JPY | -12.94% |
| 2010 Q2 | 7.28 Billion JPY | -3.37% |
| 2009 FY | 8.66 Billion JPY | 11.33% |
| 2009 Q2 | 8.94 Billion JPY | 0.0% |
| 2009 Q4 | 8.66 Billion JPY | -2.93% |
| 2009 Q3 | 8.92 Billion JPY | -0.23% |
| 2008 Q3 | 7.68 Billion JPY | 0.0% |
| 2008 Q4 | 7.78 Billion JPY | 1.24% |
| 2008 FY | 7.78 Billion JPY | 5.64% |
| 2007 FY | 7.36 Billion JPY | 3.0% |
| 2006 FY | 7.15 Billion JPY | 34.37% |
| 2005 FY | 5.32 Billion JPY | -29.66% |
| 2004 FY | 7.56 Billion JPY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Kyowa Kirin Co., Ltd. | 189.52 Billion JPY | 75.861% |
| Astellas Pharma Inc. | 1973.61 Billion JPY | 97.682% |
| Chugai Pharmaceutical Co., Ltd. | 306.96 Billion JPY | 85.096% |
| Ono Pharmaceutical Co., Ltd. | 115.06 Billion JPY | 60.24% |
| Santen Pharmaceutical Co., Ltd. | 130.33 Billion JPY | 64.898% |
| Daiichi Sankyo Company, Limited | 1763.11 Billion JPY | 97.405% |
| Otsuka Holdings Co., Ltd. | 924.92 Billion JPY | 95.054% |
| Perseus Proteomics Inc. | 295.46 Million JPY | -15383.729% |